Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity
Doris Makari, Kathryn M Jensen, Brian Harris, Hasan S Jafri, Doris Makari, Kathryn M Jensen, Brian Harris, Hasan S Jafri
Abstract
Introduction: To avoid the need for reconstitution required by lyophilized palivizumab, a liquid formulation was developed. This study assessed the safety and antidrug antibodies (ADA) of the liquid formulation of palivizumab compared with the lyophilized formulation.
Methods: This phase 4, randomized, double-blind, multicenter study included children with chronic lung disease of prematurity who were ≤24 months of age and children born prematurely with a gestational age of ≤35 weeks who were ≤6 months of age at randomization. Subjects were randomized 1:1 to 15 mg/kg of either liquid or lyophilized palivizumab administered via intramuscular injection every 30 days for a total of 5 injections. Safety was assessed based on serious adverse events (SAEs). ADA to palivizumab was assessed using blood collected at baseline and at a time point between study days 240 and 300.
Results: A total of 413 subjects were included in the analyses. The incidence of SAEs reported was 8.5% with liquid palivizumab and 5.9% with lyophilized palivizumab; none were deemed drug-related. The reported SAEs were consistent with expected conditions in this pediatric age group; there was no increase in respiratory syncytial virus (RSV) disease with liquid palivizumab. At study days 240-300, antipalivizumab antibodies were detected in none of the subjects in the liquid palivizumab group and in 1 subject in the lyophilized group. The true ADA percent positive, based on the upper limit of the 95% confidence interval (CI), was <1.5% for both treatments combined.
Conclusion: The frequency of detection of ADAs was low. The true ADA percent positive for both treatment groups combined based on the upper limit of the 95% CI was <1.5%. The type and frequency of SAEs reported were as expected, and there was no evidence of an increase in RSV disease with liquid palivizumab.
Keywords: Antidrug antibody; Children; Chronic lung disease of prematurity; Liquid; Lyophilized; Palivizumab; Premature infants; Respiratory syncytial virus disease; Safety.
Figures
References
- Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–1555. doi: 10.1016/S0140-6736(10)60206-1.
- American Academy of Pediatrics. Policy statement—modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694–1701.
- Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176:1215–1224. doi: 10.1086/514115.
- Palivizumab. Full prescribing information. Gaithersburg: MedImmune; 2014.
- La Via WV, Notario GF, Yu XQ, et al. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther. 2013;26:666–671. doi: 10.1016/j.pupt.2013.03.007.
- The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–537. doi: 10.1542/peds.102.3.531.
- Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791–1799. doi: 10.1056/NEJMoa1211917.
- Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532–540. doi: 10.1067/S0022-3476(03)00454-2.
- Mejias A, Chavez-Bueno S, Sanchez PJ. Respiratory syncytial virus prophylaxis. Neoreviews. 2005;6:e26–e31. doi: 10.1542/neo.6-1-e26.
- ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm. 1993;50:305–14.
- Data on File—Study MI-CP080. Gaithersburg: MedImmune, LLC.
- Data on File—Study MI-CP097. A phase 2, randomized, double-blind, two-period, cross-over study to evaluate the pharmacokinetics, safety and tolerability of a liquid formulation of palivizumab (MEDI-493, Synagis®), a humanized respiratory syncytial virus monoclonal antibody, in children with a history of prematurity. Gaithersburg: MedImmune, LLC; 2007.
- Gupta S, Devanarayan V, Finco D, et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal. 2011;55:878–888. doi: 10.1016/j.jpba.2011.03.038.
- Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125:e35–e51. doi: 10.1542/peds.2008-1036.
- Data on File. Gaithersburg: MedImmune.
Source: PubMed